Premium
Adjuvant chemotherapy in stage I uterine endometrial carcinoma
Author(s) -
Hirai M.,
Hirono M.,
Oosaki T.,
Hayashi Y.,
Yoshihara T.,
Itami M.
Publication year - 2002
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/s0020-7292(02)00069-3
Subject(s) - medicine , chemotherapy , adjuvant , stage (stratigraphy) , lymph , adjuvant therapy , survival rate , oncology , carcinoma , surgery , pathology , paleontology , biology
Objective: We have assessed prognostic factors and the efficacy of adjuvant chemotherapy in stage I uterine endometrial carcinoma. Methods: 251 primary surgically treated stage I patients were studied. Prognostic factors were evaluated and 5‐year and 10‐year survival rates were compared in patients with lymph‐vascular space invasion to investigate whether adjuvant chemotherapy improves survival. Results: The overall 5‐year and 10‐year survival rates were 94% and 93%. Multivariate analysis indicates that lymph‐vascular space invasion is the most significant prognostic factor in both 5‐ and 10‐year survival rates ( P< 0.001 at both times) and stage/depth of invasion is significant for the 10‐year survival rate ( P =0.04). Of 54 patients with lymph‐vascular space invasion, statistically significant differences were observed in 10‐year survival rate ( P =0.02) between patients who had surgery followed by adjuvant chemotherapy ( n =23) and patients who had surgery alone ( n =31). Toxicities were mild to moderate (30%). C onclusions: The clinical importance of lymph‐vascular space invasion and the efficacy of adjuvant chemotherapy were confirmed. This observation warrants a larger comparative study with adjuvant chemotherapy.